Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice

Area of Science:

• Oncology
• Radiotherapy
• Breast Cancer Management

Background:

• Adjuvant radiation therapy (RT) is standard after breast-conserving surgery (BCS) for most breast cancer patients.
• Traditional whole breast irradiation (WBI) regimens have been shortened through hypofractionation (3-4 weeks) and ultra-hypofractionation (5 fractions).
• Partial breast irradiation (PBI) offers a reduced treatment duration and irradiated volume alternative to WBI.

Purpose of the Study:

• To review the evolution and current standards of radiation therapy for early-stage breast cancer.
• To discuss the safety and efficacy of various RT fractionation schedules and techniques.
• To highlight future directions in breast cancer radiotherapy research.

Main Methods:

• Review of clinical trial data and established guidelines for breast cancer radiotherapy.
• Analysis of outcomes from randomized trials comparing different WBI and PBI regimens.
• Evaluation of data on regional lymph node irradiation and intraoperative RT.

Main Results:

• Hypofractionated WBI (3-4 weeks) and five-fraction WBI are now standard of care for many patients.
• Partial breast irradiation (PBI) demonstrates long-term safety and efficacy compared to WBI.
• Hypofractionated RT is safe for regional lymph nodes in BCS or mastectomy patients without reconstruction.

Conclusions:

• Modern radiation therapy for breast cancer offers shorter, effective treatment options like hypofractionated WBI and PBI.
• Ongoing research explores ultra-short RT regimens, omission of RT based on risk, and personalized approaches using genomics.